📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 19:48
510 analysed today
510
Today
133,399
All-time analysed
40,108
Positive
6,279
Negative
79,197
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Rs 55.99 Cr Revenue in Q1 FY27; Order Book Reaches Rs 165 Cr in CDMO Turnaround
Innovassynth Technologies has reported a significant operational turnaround in Q1 FY27, with revenue reaching Rs 55.99 Cr compared to Rs 12.27 Cr in the same quarter last year. The company achieved a PAT of Rs 6.74 Cr, reversing a loss of Rs 18.67 Cr YoY, with EBITDA margins expanding to 27%. The current order book stands at Rs 165 Cr, which is approximately 1.6x the total revenue of FY26 (Rs 102.35 Cr). Management is currently executing a capacity expansion in Life Sciences intended to double existing production capabilities to meet CRDMO demand.
Confidence: HIGH
What changedThe company has transitioned from an investment holding entity to an active CDMO operator, delivering its first major profitable quarter with significant revenue scale.
Why it mattersThis represents a fundamental shift in the business model; the company is now directly participating in the high-growth Indian CDMO market (14.67% CAGR) with a validated order book and healthy margins.
Q1 FY27 Revenue: Rs 55.99 CrOrder Book: Rs 165 CrOrder Book vs FY26 Revenue: 161.2%EBITDA Margin: 27%Reaction Capacity: 250 KL+
📅 Short termThe stock may react positively to the sharp turnaround in profitability and the strong visibility provided by the Rs 165 Cr order book.
📈 Long termIf the company successfully doubles its capacity and maintains its 27% margin, it could structurally re-rate as a specialized CDMO player in the nucleosides and amides space.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High geographic concentration with 90% revenue from exports
- Logistics-related challenges cited by management
- Execution risk associated with doubling manufacturing capacity
Key Highlights
Revenue from operations surged 356% YoY to Rs 55.99 Cr in Q1 FY27.
EBITDA turned positive at Rs 14.97 Cr (27% margin) vs a loss of Rs 15.53 Cr in Q1 FY26.
Total order book of Rs 165 Cr as of June 30, 2026, with Rs 84 Cr from Life Sciences.
Exports contribute approximately 90% of total revenue, focused on USA and European markets.
Current manufacturing infrastructure includes 10+ lines with a total reaction capacity exceeding 250 KL.
👀 What to Watch
Watch for the timeline and commissioning of the Life Sciences capacity expansion, as doubling capacity is critical to servicing the Rs 165 Cr order book and sustaining the 27% EBITDA margin.
Rs 11.16 Cr PBT: Innovassynth turns profitable in Q1 FY27 post-merger and Rs 69.65 Cr rights issue
Innovassynth Technologies has reported a significant operational turnaround in Q1 FY27, following its merger with ITIL and a successful capital raise. Revenue from operations reached Rs 55.99 Cr, a substantial jump from the restated Rs 12.27 Cr in the year-ago period. The company posted a Profit After Tax (PAT) of Rs 6.74 Cr, compared to a loss of Rs 18.67 Cr in Q1 FY26. This performance is supported by a Rs 69.65 Cr rights issue completed in May 2026, which has strengthened the balance sheet for its CDMO expansion.
Confidence: HIGH
What changedThe company has transitioned from an investment holding entity to an active CDMO operator following the merger with ITIL and has significantly bolstered its capital through a rights issue.
Why it mattersThis is the first clean quarter showing the combined entity's operational strength, proving the merger's ability to generate immediate profitability and revenue growth in the specialty chemicals space.
Revenue from Operations (Q1 FY27): Rs 5,598.59 LakhsProfit After Tax (Q1 FY27): Rs 673.53 LakhsRights Issue Proceeds: Rs 6,964.55 LakhsRights Issue vs Market Cap: ~14.7%Total Income Growth (YoY Restated): 354.6%
📅 Short termThe stock is likely to react positively to the sharp turnaround from losses to profitability and the successful completion of the capital raise.
📈 Long termThe structural shift into the CDMO market (projected 14.67% CAGR) positions the company for long-term growth, provided it can manage pricing pressures and talent retention.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High concentration risk as the business is now entirely dependent on the merged CDMO operations
- Pricing pressure from domestic and international competition
- Dependency on specialized R&D personnel
Key Highlights
Revenue from operations grew to Rs 55.99 Cr in Q1 FY27 from a restated Rs 12.27 Cr in Q1 FY26.
Turned around to a Profit Before Tax of Rs 11.16 Cr from a loss of Rs 18.75 Cr YoY.
Completed a rights issue of 1.74 Cr shares at Rs 40 per share, raising Rs 69.65 Cr in May 2026.
Paid-up equity share capital increased to Rs 92.86 Cr as of June 30, 2026, from Rs 75.45 Cr in March 2026.
Reported a positive EPS of Rs 0.80 for the quarter, compared to a negative EPS of Rs 2.47 in the restated previous year quarter.
👀 What to Watch
Investors should monitor the company's ability to maintain these margins in the niche nucleosides and amides segments and track the utilization of the Rs 69.65 Cr rights issue proceeds for capacity expansion.
₹6.74 Cr Profit: Innovassynth Reports Turnaround in Q1 FY27 Post-Merger Integration
Innovassynth Technologies (formerly Innovassynth Investments) reported a significant financial turnaround in Q1 FY27, posting a net profit of ₹6.74 cr compared to a restated loss of ₹18.67 cr in Q1 FY26. Revenue from operations surged to ₹55.99 cr from ₹12.27 cr (restated) in the year-ago period, reflecting the full integration of the merged ITIL entity. The company also strengthened its balance sheet by completing a ₹69.65 cr rights issue in May 2026. This quarter marks the first full period reflecting the company's transition from an investment holding firm to an active CDMO manufacturer.
Confidence: HIGH
What changedThe company has completed its structural transformation from an investment holding company to an operating specialty chemicals entity following the merger with ITIL and a successful rights issue.
Why it mattersThe financials now reflect direct participation in the high-growth Indian CDMO market (projected 14.67% CAGR) rather than indirect investment holding, providing a clearer path to cash flow generation and valuation re-rating.
Revenue (Q1 FY27): ₹55.99 crNet Profit (Q1 FY27): ₹6.74 crRights Issue Proceeds: ₹69.65 crRights Issue vs Market Cap: ~14.7%EPS (Q1 FY27): ₹0.80
📅 Short termThe stock may see positive momentum as the market reacts to the sharp turnaround from losses to profitability and the successful capital infusion.
📈 Long termThe long-term outlook depends on the company's ability to leverage its R&D in niche chemical segments and scale operations to meet the projected USD 44.63 billion Indian CDMO market by 2029.
⚠ Risk flags
- High concentration risk as 100% of operations are now tied to the merged ITIL business
- Pricing pressure from domestic and international CDMO competitors
- Sensitivity to skilled R&D personnel retention
Key Highlights
Revenue from operations grew to ₹55.99 cr in Q1 FY27, up from a restated ₹12.27 cr in Q1 FY26.
Net profit turned positive at ₹6.74 cr for the quarter, compared to a restated loss of ₹18.67 cr in the previous year's corresponding quarter.
Successfully raised ₹69.65 cr through a rights issue of 1.74 cr shares at ₹40 each, completed on May 19, 2026.
Paid-up equity share capital increased to ₹92.86 cr as of June 30, 2026, from ₹75.45 cr in March 2026.
Profit before tax stood at ₹11.16 cr for Q1 FY27, a sharp recovery from a loss of ₹18.75 cr in Q1 FY26.
👀 What to Watch
Investors should monitor the sustainability of operating margins in the newly integrated CDMO business and the utilization of the ₹69.65 cr rights issue proceeds for capacity expansion. The next key milestone is the delivery of consistent quarterly growth in the niche nucleosides and amides segments.
